Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery
Cenix BioScience GmbH announced that they have signed a research agreement with Regulus Therapeutics LLC to advance the latter's efforts in the discovery of novel therapeutic miRNA modulators.
Cenix will apply its expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells. The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic potential in the area of immunology and inflammation.
"Following the long-standing relationship and mutual respect shared with several key members of the starting team at Regulus, we at Cenix are very much looking forward to working together to drive this ground-breaking discovery program forward" said Dr. Christophe Echeverri, CEO/CSO of Cenix.
"Regulus is committed to discovering and developing novel microRNA-targeted therapeutics and adding to a large and growing body of knowledge on how individual microRNAs function within the cell," said Peter S. Linsley, Ph.D. CSO of Regulus. "We look forward to working collaboratively with Cenix to identify interesting microRNA-targeted drug candidates."
No further terms of the agreement were released.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Alligator Bioscience´s ADC-1004 for treatment of ischemia reperfusion injury reduced myocardial infarct size
Expansion of Sartorius Stedim Cellca - Laboratory and office facility to be constructed on the site by 2019

Diagnosing cancer in minutes - Identify tumour margins directly in the surgery room: Refined Laser Systems raises €2.7m
Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology Drugs

HIV-1: The undercover agent - The AIDS virus HIV-1 goes largely unnoticed by T-cells of the immune system thanks to an ingenious propagation strategy

Battling bacteria with viruses - New agents to fight multidrug-resistant germs
Hungarian-based SOLVO and MDS Pharma Services Team Up to Offer ABC Transporter Assays
Category:Ayurveda

Cell-free production of bacteriophages - Viruses help combat antibiotic-resistant bacteria
